South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals
2.3.2021 17:00:00 EET | Business Wire | Press release
The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity.
Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore.
The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three.
|
% Female board level representation by country |
|
|
France |
43.8% |
|
UK |
36.0% |
|
Australia |
34.0% |
|
Germany |
32.5% |
|
Spain |
29.8% |
|
US |
29.8% |
|
South Africa |
28.5% |
|
Singapore |
17.3% |
|
India |
17.0% |
The public sector – meaning members of Parliament or equivalent – is faring slightly better. The average across the countries surveyed is 33.2% - a marginal difference compared to the private sector – but two thirds (6 out of 9) countries showed more promising gender parity in their governments compared to on their boards. South Africa led the way in the public sector with 44% of its MPs being women – a huge step up from its 28.5% parity at board level – though France is the most gender-diverse nation when taking an average across both its parliament and the boards of its largest companies. The average across both sectors is 32% female representation, whereas France is a leader with 40.4% parity overall.
|
% Female parliament representation by country |
|
|
South Africa |
44.0% |
|
Spain |
42.0% |
|
Australia |
38.0% |
|
France |
37.0% |
|
UK |
34.0% |
|
Germany |
33.0% |
|
Singapore |
30.0% |
|
US |
27.0% |
|
India |
14.0% |
This year’s annual report demonstrates modest progress compared with 2020. Representation of women in the private sector has increased marginally in the United States (1.2%), United Kingdom (3%) and Australia (0.6%), as well as in the parliaments in Australia (1%) and the United States (3.5%), which had a record year for women elected. India remains the least gender diverse country studied with representation of women under 20% across both public (14%) and private sectors (17%).
Beth Sehgal, global director of diversity, equity, and inclusion at Kearney, comments:
“It’s positive to see businesses and governments move towards equal representation as women hold an increasing number of high-ranking positions. However, progress has been slow, and the gender leadership gap endures. France is leading the way for private sector representation and South Africa ranks number one for public sector diversity, and the progress of these two countries should provide benchmarks as we work towards achieving gender parity worldwide.
“Diversity, Equity and Inclusion initiatives will need to be prioritized, particularly in countries lagging behind. Diversity has regularly been linked to high-performance with a variety of perspectives encouraging fresh ideas and preventing the dreaded group think. As the economy rebuilds from the aftermath of coronavirus, it will be crucial women are fairly represented in both public and private sector roles to help assist in its recovery and to avoid a regression on gender equality or “she-cession”.”
About Kearney
As a global consulting partnership in more than 40 countries, our people make us who we are. We’re individuals who take as much joy from those we work with as the work itself. Driven to be the difference between a big idea and making it happen, we help our clients break through. Learn more at Kearney.com.
About the research
Kearney‘s Gender Equality Report 2021 was based on research using publicly available data across nine countries – UK, US, France, Germany, Spain, Australia, India and Singapore – regarding the representation of women at board level and in their respective parliaments. Board information was gathered using the support of Factset.
Read the report: https://www.kearney.com/web/international-womens-day/article/?/a/the-equality-dilemma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005622/en/
Contact information
Press contact
Sophie Mellish
Rostrum – PR consultants to Kearney
s.mellish@rostrum.agency
+44 7789 712 597
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
